z-logo
open-access-imgOpen Access
What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy
Author(s) -
Patricia Zondervan,
Axel Bex
Publication year - 2022
Publication title -
kidney cancer
Language(s) - English
Resource type - Journals
eISSN - 2468-4570
pISSN - 2468-4562
DOI - 10.3233/kca-220004
Subject(s) - renal cell carcinoma , medicine , nephrectomy , clinical trial , oncology , targeted therapy , systemic therapy , nivolumab , immunotherapy , kidney , cancer , breast cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom